Core Insights - TC BioPharm has completed dosing of Cohort A patients in the ACHIEVE Phase 2B UK clinical trial, focusing on allogeneic gamma-delta T cell therapies for cancer treatment [1] - Preliminary data indicates favorable safety and efficacy in Cohort A patients with relapse or refractory acute myeloid leukemia (AML), with no drug-related adverse events reported [2][9] - The trial aims to evaluate the effectiveness and tolerability of TCB008 in patients who have exhausted available therapies [3] Recruitment and Trial Details - Recruitment for Cohort A was re-initiated in July 2024 with higher doses of TCB008, reaching a cumulative dose of up to one billion gamma-delta T cells [4] - The trial has seen expedited recruitment due to strong interest from investigators and patients, leading to the conclusion of Cohort A enrollment while recruitment for Cohort B continues [4] - The ACHIEVE trial is an open-label Phase II study dedicated to assessing TCB008's efficacy and safety in patients with AML and myelodysplastic syndromes [3] Company Position and Future Directions - TC BioPharm is recognized as a leader in developing gamma-delta T cell therapies and is the first to conduct pivotal clinical studies in oncology [7] - The company is focused on how to prolong or enhance the therapeutic effect of TCB008, with ongoing data reviews to define next steps, including potential combinations with other treatments [3][5] - The early safety and efficacy data reinforces the company's confidence in TCB008 as a viable treatment option for patients with significant unmet clinical needs [5]
TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial